Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DDO | Q99489 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28105244 | 0.85 | HCAR2 (0.53) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL28999567 | 0.82 | CYP11B1 (0.48) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL30777432 | 0.82 | HCAR2 (0.59) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL7817677 | 0.82 | HCAR2 (0.59) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL7674347 | 0.82 | HCAR2 (0.53) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL846393 | 0.80 | CYP2C9 (0.61) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL7225354 | 0.80 | HCAR2 (0.57) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1244630 | 0.80 | KDM4E (0.57) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL30281282 | 0.80 | CYP2C9 (0.61) | HCAR2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6466932 | 0.78 | ATM (0.59) | ALDH1A1KDM4EPOLBLMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115590-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12215096-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4335499-A2 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | Foresee Pharmaceuticals USA, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-3793992-B1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA INC (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | FORESEE PHARMACEUTICALS USA, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2021-07-15 | — | — | US | disclosed |
| EP-3793992-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | Foresee Pharmaceuticals USA, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS CO., LTD (TW) | 2019-11-21 | — | — | US | disclosed |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS CO., LTD (TW) | 2019-11-21 | — | — | US | disclosed |
| CN-110016025-A | A kind of immunomodulator | 成都先导药物开发股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214340-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | HCAR2 604/4885ALDH1A1 2785/4885KDM4E 2499/4885 |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | HCAR2 604/4885ALDH1A1 2785/4885KDM4E 2499/4885 |
| US-11739080-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | HCAR2 604/4885ALDH1A1 2785/4885KDM4E 2499/4885 |
| US-12215096-B2 | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | MMP12, MMP1, MMP11 | HCAR2 604/4885ALDH1A1 2785/4885KDM4E 2499/4885 |
| US-20250115590-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | HCAR2 604/4885ALDH1A1 2785/4885KDM4E 2499/4885 |
| US-20190352288-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | HCAR2 604/4885ALDH1A1 2785/4885KDM4E 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.